A Comparative Crossover Study on the Safety, Efficacy, and Patient Reported Satisfaction of the PureWick™ System With an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 15
- Locations
- 2
- Primary Endpoint
- Performance of the PureWick MEC in the Home Setting
Study Overview
Brief Summary
This post-market study will assess the performance of and user satisfaction with the PureWick™ Male External Catheter in a home setting. The study will also observe safety of the study device and collect information from participants about their experience using the device.
Detailed Description
Approximately 15 men requiring the use of diapers or pads at night for urine management will take part in this prospective, open-label, crossover trial. Participants will be 1:1 randomized to a treatment sequence using two devices: the PureWick™ System (PureWick™ Male External Catheter & PureWick™ Urine Collection System) and the UltraFlex™ Self-Adhering Male External Catheter. Participants will use each urine management device overnight while sleeping for a period of 7 days with a 2-day washout period in between. Total duration of participation is approximately 16 days. The primary efficacy endpoint is the mean capture rate. The primary safety endpoint is the number of device-related AEs requiring medical intervention. Capture rates and Adverse Events are assessed daily throughout each 7-day treatment phase. Sleep disturbance is assessed at baseline and every 7 days during treatment. End of study preference questionnaire is completed at the end of treatment. Device adherence is assessed by the proportion of device wear nights that the study device became dislodged. Tolerability is assessed by number of nights of actual device use.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to — (Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult male participants ≥ 65 years of age at the time of signing the informed consent
- •Male anatomy at the time of enrollment
- •Currently use diapers, pads, or equivalent at night for urine output management
- •Willing to comply with all study procedures in this protocol
- •Provision of signed and dated informed consent form
Exclusion Criteria
- •Has frequent episodes of bowel incontinence; or
- •Has chronic urinogenital infections, active genital herpes; or
- •Has Urinary retention; or
- •Has experience using study devices in the home setting within the last year; or
- •Is agitated, combative, and/or uncooperative and may remove the external catheter; or
- •Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or
- •Any other condition that, in the opinion of the investigator, would preclude them from participating in the study; or
- •Is considered a vulnerable population.
Arms & Interventions
Treatment Sequence 2
UltraFlex™ is used first, followed by cross-over to PureWick™ System
Intervention: PureWick™ System (Device)
Treatment Sequence 2
UltraFlex™ is used first, followed by cross-over to PureWick™ System
Intervention: UltraFlex™ Self-Adhering Male External Catheter (Device)
Treatment Sequence 1
PureWick™ System is used first, followed by cross-over to UltraFlex™
Intervention: PureWick™ System (Device)
Treatment Sequence 1
PureWick™ System is used first, followed by cross-over to UltraFlex™
Intervention: UltraFlex™ Self-Adhering Male External Catheter (Device)
Outcomes
Primary Outcomes
Performance of the PureWick MEC in the Home Setting
Time Frame: Daily for 7 days during each treatment phase
Capture rate following void (captured as % of urine captured by device and collected in canister, measured by weight). Prior to each nightly use, the weight of the empty urine collection canister and the weight of a dry absorbent pad are collected. Participants use the device overnight while sleeping with the absorbent pad underneath them. The next morning, the post-void weight of the urine collection canister and the post-void weight of the absorbent pad are collected. Capture rate is calculated as the weight of captured urine (post-void canister weight - pre-void canister weight) / total urine volume (captured urine (post-void canister weight - pre-void canister weight) + leaked urine (post-void pad weight - pre-void pad weight)) \* 100.
Number of device-related Adverse events requiring medical intervention
Time Frame: Daily for 7 days during each treatment phase
Number of device-related Adverse events requiring medical intervention, such as new prescription medication, surgery or procedure, or therapy ordered by a medical provider to treat or manage the adverse event, in each treatment group.
Secondary Outcomes
- Participant Device Tolerance(After completion of each 7-day treatment phase or at the time of treatment discontinuation, whichever comes first.)
- Device Adherence/Dislodgement(After completion of each 7-day treatment phase or at the time of treatment discontinuation, whichever comes first.)
- Participant Device Preference(After completion of both 7-day treatment phase or at the time of treatment discontinuation, whichever comes first.)